Feline idiopathic cystitis: does amitriptyline versus placebo reduce recurrence of signs? — MAYBE (weak evidence)

In cats with recurrent idiopathic cystitis, does amitriptyline vs placebo reduce recurrence of signs?

Shelf #713 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence): The only placebo-controlled evidence is for SHORT-TERM (7-day) amitriptyline, and it found no benefit. Kruger 2003 (PMID: 12675297; randomised controlled trial, 31 cats with acute, nonobstructive, idiopathic lower urinary tract disease; amitriptyline 5 mg/day, n = 16, vs placebo, n = 15, for 7 days) found clinical signs resolved by day 8 in 8 amitriptyline-treated and 10 control cats, with no apparent differences in likelihood or rate of recovery from pollakiuria or hematuria; over 6, 12 and 24 months of follow-up, clinical signs recurred significantly faster and more frequently in amitriptyline-treated than control cats overall, although after recurrences within 21 days of treatment were excluded the risk of recurrence was similar in both groups. Kraijer 2003 (PMID: 12765630; controlled study, 36 cats with idiopathic feline lower urinary tract disease, 24 in the final assessment; amitriptyline 10 mg once daily vs placebo for 7 days, all cats also receiving antibiotics) found no significant difference in symptom severity between groups and concluded a 7-day course was not effective. For this shelf's own population — cats with RECURRENT idiopathic cystitis treated long-term — there is no controlled trial at all: the only long-term record (Chew 1998, PMID: 9810383; 15 cats with severe recurrent idiopathic cystitis that had failed other treatments, amitriptyline 10 mg daily for up to 12 months, no control group) found 11/15 cats free of owner-observed signs in the first 6 months and 9/15 in the next 6 months, a result that cannot be separated from the natural waxing-and-waning course of the disease without a placebo arm, and it is documented in the synthesis, not carded. Design class (a): randomisation and blinding are established by a carded record answering this shelf's own comparison — Kraijer 2003 carries publication type Randomized Controlled Trial and MeSH Double-Blind Method for amitriptyline vs placebo in feline idiopathic lower urinary tract disease; Kruger 2003 is likewise a randomised controlled trial of the same comparison, though its record does not state blinding. The stamp is MAYBE (weak evidence), not a stronger null, because both controlled trials test only 7 days of treatment (the drug's postulated benefit is long-term), the samples are small, Kraijer 2003 lost a third of its cats before final assessment and gave all cats antibiotics alongside, neither trial enrolled the recurrent population this shelf names, and the one-year recurrence question has never been tested under control. In plain terms: short-term amitriptyline made no difference in the trials done; whether long-term amitriptyline reduces recurrence in recurrent cystitis is unknown. Drafted Nov 10, 2026 (VetMed build, topic #713); all figures from the abstracts fetched and verified at drafting.

Kruger 2003: 7 days of amitriptyline did not speed recovery in acute idiopathic lower urinary tract disease — signs resolved by day 8 in 8 amitriptyline cats vs 10 placebo cats, and signs later recurred faster and more often in the amitriptyline group

Randomized controlled trial (record's own wording; publication types: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't; the record does not state that treatment was blinded)

Who: Cats: 31 untreated male and female cats with acute, nonobstructive, idiopathic lower urinary tract disease, in a randomised controlled trial. Cats received amitriptyline (5 mg/day; n = 16) or a placebo (n = 15) for 7 days and were monitored for pollakiuria, hematuria and adverse events; they were reexamined 1 month after treatment and owners were interviewed by telephone 6, 12 and 24 months after treatment. Two amitriptyline-treated cats were excluded from analyses because of acquired urinary tract infection.

Result: Clinical signs resolved by day 8 in 8 amitriptyline-treated and 10 control cats. There were no apparent differences in likelihood or rate of recovery from pollakiuria or hematuria between groups. Overall, clinical signs recurred significantly faster and more frequently in amitriptyline-treated than control cats; however, after excluding recurrences within 21 days of treatment, risk of recurrence was similar in both groups. Increasing age was significantly associated with increased likelihood and rate of recovery from hematuria and with decreased risk of recurrence of signs. The authors conclude that short-term amitriptyline treatment has no benefit in terms of resolution of pollakiuria and hematuria in cats with idiopathic lower urinary tract disease and may be associated with an increased risk of recurrence.

Watch out: The cats had ACUTE, first-presentation disease, not the recurrent cystitis this shelf names, and treatment lasted only 7 days — the trial tests short-term amitriptyline, not the months-long treatment used for recurrent cases. The recurrence disadvantage for amitriptyline depends on counting recurrences in the first 21 days after treatment (plausibly still the index episode resolving); with those excluded, recurrence risk was similar. Small numbers: 16 vs 15 cats, falling to 14 analysed in the amitriptyline arm.

Kruger JM, Conway TS, Kaneene JB, Perry RL, Hagenlocker E, Golombek A, Stuhler J. Randomized controlled trial of the efficacy of short-term amitriptyline administration for treatment of acute, nonobstructive, idiopathic lower urinary tract disease in cats. J Am Vet Med Assoc. 2003;222(6):749-58. PMID: 12675297. Registry ID: none in the record. MeSH: Acute Disease · Adrenergic Uptake Inhibitors/therapeutic use* · Age Factors · Amitriptyline/therapeutic use* · Animals · Cat Diseases/drug therapy* · Cats · Female · Male · Prospective Studies · Recurrence · Risk Factors · Treatment Outcome · Urinary Tract Infections/drug therapy, veterinary*

Kraijer 2003: a 7-day course of amitriptyline 10 mg was not effective in idiopathic feline lower urinary tract disease — no significant difference in symptom severity versus placebo in 24 assessed cats

Controlled clinical study (publication types: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't; MeSH includes Double-Blind Method)

Who: Cats: 36 cats suffering from idiopathic feline lower urinary tract disease, selected by veterinary practitioners and treated with placebo or 10 mg amitriptyline once daily; all animals received concomitant antibiotic treatment. A total of 24 cats were included in the final assessment of the results. The severity of symptoms before and after treatment was compared between groups.

Result: The severity of symptoms before and after treatment showed no significant difference between the amitriptyline and placebo groups. The authors conclude that the 7-day course of 10 mg amitriptyline was not effective in the treatment of idiopathic feline lower urinary tract disease, is not beneficial as a short-term therapy where the therapeutic result depends on peripheral effects of the drug, and that long-term effects (4 or more weeks after the start of therapy) need to be further investigated.

Watch out: A third of the enrolled cats (12/36) were not in the final assessment, with no reasons given in the record; every cat also received antibiotics, an uncontrolled co-treatment in a disease that is by definition non-bacterial; treatment was 7 days only; and the abstract prints no group sizes for the final 24, no severity scores and no effect estimate, so the null rests on the authors' significance statement alone.

Kraijer M, Fink-Gremmels J, Nickel RF. The short-term clinical efficacy of amitriptyline in the management of idiopathic feline lower urinary tract disease: a controlled clinical study. J Feline Med Surg. 2003;5(3):191-6. PMID: 12765630. Registry ID: none in the record. MeSH: Administration, Oral · Adrenergic Uptake Inhibitors/administration & dosage, therapeutic use* · Amitriptyline/administration & dosage, therapeutic use* · Animals · Cat Diseases/drug therapy*, pathology · Cats · Double-Blind Method · Female · Male · Netherlands · Severity of Illness Index · Treatment Outcome · Urologic Diseases/drug therapy, veterinary*

Synthesis: two small placebo-controlled trials agree that 7-day amitriptyline does not help feline idiopathic lower urinary tract disease; long-term treatment of recurrent cystitis has never been placebo-tested — MAYBE (weak evidence)

Synthesis

Who: Synthesis of the two cards above: Kruger 2003 (31 cats, acute nonobstructive idiopathic lower urinary tract disease, amitriptyline 5 mg/day vs placebo for 7 days, recurrence followed to 24 months) and Kraijer 2003 (36 cats enrolled, 24 assessed, idiopathic feline lower urinary tract disease, amitriptyline 10 mg/day vs placebo for 7 days, all cats also on antibiotics).

Result: (1) Resolution of signs: no benefit in either trial — resolution by day 8 in 8 amitriptyline-treated vs 10 control cats (Kruger 2003), and no significant difference in symptom severity (Kraijer 2003). (2) Recurrence: in the only controlled follow-up, signs recurred significantly faster and more frequently after short-term amitriptyline than after placebo when early (within 21 days) recurrences were counted, and at a similar risk when they were not (Kruger 2003) — at minimum, no recurrence benefit from a 7-day course. (3) The long-term question: Chew 1998 (PMID: 9810383), a prospective UNCONTROLLED study in exactly this shelf's population — 15 cats with severe recurrent idiopathic cystitis that had failed other treatments, given amitriptyline 10 mg every evening for 12 months or until signs recurred — found 11/15 cats free of owner-observed signs during the first 6 months and 9/15 during the next 6 months, with cystoscopic abnormalities persisting in all cats and somnolence (2/15 initially), weight gain (7/9 completers), decreased coat quality (8/9 completers) and small cystic calculi in 4 cats during the first 6 months; without a control group this cannot be credited to the drug, so it is documented here and not carded. The 2025 systematic review of recurrent feline idiopathic cystitis management (Macleod 2025, PMID: 40147044) reads the same three amitriptyline studies the same way: two indicating short-term use is not supported, and one long-term study suggesting it may be useful in some refractory cases. (4) Design class (a): randomisation and blinding established by the Kraijer 2003 record (Randomized Controlled Trial publication type; Double-Blind Method MeSH) for this shelf's own comparison.

Watch out: One-home check at drafting: PMIDs 12675297, 12765630 and 9810383 do not appear in any other pack on disk; PMID 40147044 (the 2025 systematic review) is a claim-carrier on Shelf #711 (pheromone therapy for feline idiopathic cystitis) and is cross-pointed here in the synthesis only, not re-carded. Neighbouring shelves: pheromone therapy is Shelf #711 and pentosan polysulfate is Shelf #712 — different interventions in the same disease. The central gap stands: no trial has randomised cats with RECURRENT idiopathic cystitis to long-term amitriptyline or placebo, so this shelf's stamp is 'we do not know' for long-term use, alongside a clear short-term null. If such a trial is published, this pack should be rebuilt.

Synthesis of Kruger JM et al. PMID: 12675297; Kraijer M et al. PMID: 12765630; Chew DJ et al. PMID: 9810383; Macleod B et al. PMID: 40147044. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.